Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.
Saved in:
| Title: | Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. |
|---|---|
| Authors: | Xu, XueYin1 (AUTHOR), Tang, Lian1 (AUTHOR), Piao, XiangHua2 (AUTHOR), Zhan, ShaoQing1 (AUTHOR), Chen, Yong1 (AUTHOR) chenyong20242024@126.com, Feng, PanFeng1,3,4 (AUTHOR) 929083891@qq.com |
| Source: | PLoS ONE. 5/14/2026, Vol. 21 Issue 5, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0349044 |
